{"log_id": 1574786683813047144, "direction": 0, "words_result_num": 64, "words_result": [{"probability": {"variance": 0.00022, "average": 0.992484, "min": 0.936275}, "location": {"width": 308, "top": 132, "height": 37, "left": 144}, "words": "4)以往曾用细胞毒或放射治疗的患者"}, {"probability": {"variance": 0.00012, "average": 0.996316, "min": 0.943211}, "location": {"width": 910, "top": 136, "height": 57, "left": 160}, "words": "在治疗开始前及治疗期间随访下列检测:周围血象、血浆凝血因子、血糖、血清淀粉酶、血尿酸、肝功能、肾功能"}, {"probability": {"variance": 2.3e-05, "average": 0.997313, "min": 0.978964}, "location": {"width": 380, "top": 177, "height": 42, "left": 100}, "words": "骨髓涂片分类、血清钙、中枢神经系统功能等"}, {"probability": {"variance": 0.000194, "average": 0.994905, "min": 0.908661}, "location": {"width": 939, "top": 183, "height": 57, "left": 138}, "words": "5、由于本品能进一步抑制患者的免疫机制,并增加所接种病毒的增殖能力、毒性及不良反应,故在接受本品治疗"}, {"probability": {"variance": 9e-06, "average": 0.99758, "min": 0.985576}, "location": {"width": 789, "top": 214, "height": 51, "left": 101}, "words": "的3个月内不宜接受活病毒疫苗接种,另与患者密切接触者的口服脊髓灰质炎疫苗时间亦应推迟"}, {"probability": {"variance": 0.000188, "average": 0.996069, "min": 0.9083}, "location": {"width": 932, "top": 255, "height": 56, "left": 139}, "words": "(1)患者必须住院,在对肿瘤化疗有经验的医生指导下治疗,每次注射前须备有抗过敏反应的药物(包括肾上腺素"}, {"probability": {"variance": 0.00012, "average": 0.992114, "min": 0.97338}, "location": {"width": 84, "top": 260, "height": 26, "left": 165}, "words": "给药说明"}, {"probability": {"variance": 1.1e-05, "average": 0.997283, "min": 0.986651}, "location": {"width": 513, "top": 295, "height": 42, "left": 103}, "words": "抗组胺药物、静脉用的类固醇药物如地塞米松等)及抢救器械"}, {"probability": {"variance": 0.000172, "average": 0.993798, "min": 0.931428}, "location": {"width": 938, "top": 304, "height": 57, "left": 143}, "words": "(2)凡首次采用本品或已用过本品但已停药一周或一周以上的患者,在注射本品前须做皮试。皮试的药液可按下列"}, {"probability": {"variance": 0.000917, "average": 0.988448, "min": 0.835937}, "location": {"width": 972, "top": 326, "height": 60, "left": 113}, "words": "方法制备:加5ml灭菌注射用水或氯化钠注射液入小瓶内摇动,使小瓶内10000单位的门冬酰胺酶溶解,抽取0.1ml(每"}, {"probability": {"variance": 0.001069, "average": 0.987633, "min": 0.794909}, "location": {"width": 967, "top": 349, "height": 59, "left": 115}, "words": "ml含2000单位),注入另一含9.9ml稀释液的小瓶内,制成浓度约为1ml含20单位的皮试药液。用0.1ml皮试液(约"}, {"probability": {"variance": 2.4e-05, "average": 0.997433, "min": 0.979473}, "location": {"width": 942, "top": 375, "height": 57, "left": 107}, "words": "为2.0单位)做皮试,至少观察1小时,如有红斑或风团即为皮试阳性反应。患者必须皮试阴性才能接受本品治疗"}, {"probability": {"variance": 1.4e-05, "average": 0.997942, "min": 0.980026}, "location": {"width": 922, "top": 399, "height": 54, "left": 148}, "words": "3)应从静脉大量补充液体,碱化尿液,口服别嘌醇,以预防白血病或淋巴瘤患者发生高尿酸血症和尿酸性肾病"}, {"probability": {"variance": 0.000183, "average": 0.99581, "min": 0.912649}, "location": {"width": 750, "top": 427, "height": 51, "left": 152}, "words": "4)由于使用本品后会很快产生抗药性,故本品不宜用作急淋等患者缓解后的维持治疗方案"}, {"probability": {"variance": 0.00035, "average": 0.992738, "min": 0.896082}, "location": {"width": 938, "top": 442, "height": 59, "left": 151}, "words": "5)本品可经静滴、静注或肌注给药。静注前必须用灭菌注射用水或氯化钠注射液加以稀释,每10000单位的小瓶"}, {"probability": {"variance": 0.006591, "average": 0.972582, "min": 0.484883}, "location": {"width": 968, "top": 468, "height": 57, "left": 109}, "words": "稀释液量为5ml。静注给药时,本度经正在输注的氯化钠或葡萄糖注射液的侧管注入,静注的时间不得短于半小时"}, {"probability": {"variance": 0.00135, "average": 0.990891, "min": 0.737706}, "location": {"width": 969, "top": 493, "height": 57, "left": 110}, "words": "静滴法给药,本品要先用等渗液如氯化钠或葡萄糖注射液稀释,然后加入氯化钠或5%葡萄糖注射液中滴入。肌内注射"}, {"probability": {"variance": 0.002248, "average": 0.987548, "min": 0.700205}, "location": {"width": 910, "top": 517, "height": 56, "left": 113}, "words": "先要在含本品1000单位的小瓶内加入2氯化钠注射液加以稀释,每一肌注部位每一次的肌注量不应超过2m"}, {"probability": {"variance": 0.005158, "average": 0.973703, "min": 0.608589}, "location": {"width": 696, "top": 545, "height": 49, "left": 151}, "words": "不论经静脉或肌内注射稀释液一定要呈澄清才能使用,且要在稀释后8小时内使用"}, {"probability": {"variance": 0.0002, "average": 0.993994, "min": 0.913641}, "location": {"width": 941, "top": 586, "height": 55, "left": 152}, "words": "由不能排除本品有潜在的致畸胎、致突变和致继发性癌的作用,妊娠3个月内的孕妇避免使用。由于考虑到本品"}, {"probability": {"variance": 7e-06, "average": 0.998224, "min": 0.991972}, "location": {"width": 212, "top": 587, "height": 27, "left": 111}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.000461, "average": 0.990563, "min": 0.902711}, "location": {"width": 450, "top": 624, "height": 42, "left": 118}, "words": "对婴儿的危害在哺乳期间接受治疗的乳母应停止哺乳"}, {"probability": {"variance": 5.2e-05, "average": 0.993439, "min": 0.980063}, "location": {"width": 103, "top": 664, "height": 22, "left": 112}, "words": "【儿童用药"}, {"probability": {"variance": 0.005728, "average": 0.966734, "min": 0.702841}, "location": {"width": 283, "top": 673, "height": 40, "left": 157}, "words": "未进往该项实验且无可靠参考文献"}, {"probability": {"variance": 0, "average": 0.999368, "min": 0.998837}, "location": {"width": 91, "top": 708, "height": 27, "left": 113}, "words": "【老年用药"}, {"probability": {"variance": 1.1e-05, "average": 0.996325, "min": 0.98919}, "location": {"width": 282, "top": 722, "height": 37, "left": 157}, "words": "未进行该项实验且无可靠参考文献"}, {"probability": {"variance": 0.000788, "average": 0.99069, "min": 0.824696}, "location": {"width": 914, "top": 747, "height": 56, "left": 184}, "words": "泼尼松或促皮质素或长春新碱与本品同用时,会增强本品的致高血糖作用,并可能增多本品引起的神经病变及"}, {"probability": {"variance": 0, "average": 0.999265, "min": 0.998368}, "location": {"width": 140, "top": 751, "height": 33, "left": 116}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.006838, "average": 0.980129, "min": 0.459114}, "location": {"width": 890, "top": 773, "height": 57, "left": 120}, "words": "红细胞生成紊乱的危险性,但有报道如先用前述各药后再用本品,则毒性似较先用本品或同时用两药者为轻"}, {"probability": {"variance": 0.014627, "average": 0.96403, "min": 0.390096}, "location": {"width": 939, "top": 795, "height": 58, "left": 156}, "words": "2、由于本品有增高尿酸的浓度,当与别嘌醇或秋水仙碱、磺吡酮等抗痛风药合用时,要调节上述抗痛风药的"}, {"probability": {"variance": 0.011194, "average": 0.971783, "min": 0.415477}, "location": {"width": 905, "top": 820, "height": 56, "left": 121}, "words": "剂量以控制高尿酸血症痛风e般抗痛风药选用别嘌醇,因该药可阻止或逆转门冬酰胺酶引起的高尿酸血症"}, {"probability": {"variance": 3e-05, "average": 0.996889, "min": 0.973157}, "location": {"width": 626, "top": 850, "height": 49, "left": 159}, "words": "3、糖尿病患者用本品时及治疗后,均须注意调节口服降糖药或胰岛素的剂量"}, {"probability": {"variance": 0.002798, "average": 0.988569, "min": 0.629012}, "location": {"width": 903, "top": 865, "height": 56, "left": 190}, "words": "本品与硫唑嘌呤、苯丁酸氮芥、环磷酰胺、环孢素、巯嘌呤、单克隆抗体CD3或放射疗法合用时,可提高疗效"}, {"probability": {"variance": 1.3e-05, "average": 0.99878, "min": 0.981736}, "location": {"width": 473, "top": 906, "height": 39, "left": 126}, "words": "因而应考虑减少化疗药物、免疫抑制剂或放射疗法的剂量"}, {"probability": {"variance": 0.000126, "average": 0.995805, "min": 0.929084}, "location": {"width": 945, "top": 912, "height": 58, "left": 160}, "words": "5、本品与甲氨蝶呤同用时,可通过抑制细胞复制的作用而阻断甲氨蝶呤的抗肿瘤作用。有研究表明如门冬酰胺酶"}, {"probability": {"variance": 9.7e-05, "average": 0.996264, "min": 0.935022}, "location": {"width": 977, "top": 936, "height": 57, "left": 128}, "words": "在给甲氨蝶呤9~10日前应用或在给甲氨蝶呤后24小时内应用,可以避免产生抑制甲氨蝶呤的抗肿瘤作用,并可减少"}, {"probability": {"variance": 3.7e-05, "average": 0.997549, "min": 0.97313}, "location": {"width": 340, "top": 980, "height": 37, "left": 129}, "words": "甲氨蝶呤对胃肠道和血液系统的不良反应"}, {"probability": {"variance": 8e-06, "average": 0.99735, "min": 0.992234}, "location": {"width": 88, "top": 1013, "height": 23, "left": 126}, "words": "【药物过量"}, {"probability": {"variance": 3e-06, "average": 0.998349, "min": 0.99359}, "location": {"width": 283, "top": 1027, "height": 34, "left": 166}, "words": "未进行该项实验且无可靠参考文献"}, {"probability": {"variance": 1.1e-05, "average": 0.997674, "min": 0.986922}, "location": {"width": 944, "top": 1054, "height": 53, "left": 166}, "words": "门冬酰胺酶为取自大肠杆菌的酶类制剂,属周期特异性抗癌药,能将血清中的门冬酰胺水解为门冬氨酸和氨,而门"}, {"probability": {"variance": 1e-06, "average": 0.999219, "min": 0.997536}, "location": {"width": 102, "top": 1060, "height": 23, "left": 127}, "words": "【药理毒理】"}, {"probability": {"variance": 9.9e-05, "average": 0.995539, "min": 0.946633}, "location": {"width": 981, "top": 1077, "height": 56, "left": 130}, "words": "冬酰胺是细胞合成蛋白质及增殖生长所必需的氨基酸。正常细胞有自身合成门冬酰胺的功能,而急性白血病等肿瘤细胞"}, {"probability": {"variance": 0.000142, "average": 0.994382, "min": 0.94048}, "location": {"width": 969, "top": 1097, "height": 60, "left": 132}, "words": "则无此功能,因而当用本品使门冬酰胺急剧缺失时,肿瘤细胞因既不能从血中取得足够的门冬酰胺,亦不能自身合成"}, {"probability": {"variance": 0.000217, "average": 0.994362, "min": 0.907955}, "location": {"width": 973, "top": 1122, "height": 58, "left": 132}, "words": "使其蛋白质合成受障碍,增殖受抑制,细胞大量破坏而不能生长、存活,达到抗肿瘤的作用。本品亦能干扰细胞DNA"}, {"probability": {"variance": 0.001138, "average": 0.987073, "min": 0.857895}, "location": {"width": 783, "top": 1152, "height": 54, "left": 135}, "words": "RA的合成,可能作用于细胞Gt增殖周期中,为抑制该期细胞分裂的细胞周期特异性药。"}, {"probability": {"variance": 8e-06, "average": 0.998109, "min": 0.98599}, "location": {"width": 935, "top": 1192, "height": 57, "left": 172}, "words": "本品经肌肉或静脉途径吸收,血浆蛋白结合率约30%,吸收后能在淋巴液中测出,但在脑脊液中的浓度很低。注射"}, {"probability": {"variance": 1e-06, "average": 0.998905, "min": 0.997695}, "location": {"width": 111, "top": 1198, "height": 29, "left": 131}, "words": "【药代动力学"}, {"probability": {"variance": 0.005231, "average": 0.987519, "min": 0.47829}, "location": {"width": 981, "top": 1216, "height": 61, "left": 134}, "words": "本品后,血中门冬酰胺浓度立即下降到不能测出的水平,提示本品进入体内后,很快就开始起效。经肌内注射的血浆"}, {"probability": {"variance": 0.00354, "average": 0.98335, "min": 0.648949}, "location": {"width": 968, "top": 1242, "height": 54, "left": 137}, "words": "t/为39~49小时,静注的血浆t为8~30小时。肌注后的达峰时间为12~24小时,但停用本品后的23~33日"}, {"probability": {"variance": 0.000223, "average": 0.993001, "min": 0.934618}, "location": {"width": 601, "top": 1275, "height": 47, "left": 139}, "words": "血浆中还可以测出门冬酰胺,本品排泄似呈双相性,仅有微量呈现于尿中"}, {"probability": {"variance": 0.000125, "average": 0.994656, "min": 0.947128}, "location": {"width": 398, "top": 1307, "height": 37, "left": 142}, "words": "【贮藏】遮光、密闭、冷处(2~10℃)保存"}, {"probability": {"variance": 2.3e-05, "average": 0.996846, "min": 0.98643}, "location": {"width": 245, "top": 1335, "height": 32, "left": 146}, "words": "包装】西林瓶,1瓶/盒"}, {"probability": {"variance": 1.7e-05, "average": 0.995801, "min": 0.988165}, "location": {"width": 313, "top": 1354, "height": 37, "left": 138}, "words": "【有效期】(1)24个月(5000单位)"}, {"probability": {"variance": 6.5e-05, "average": 0.995552, "min": 0.965844}, "location": {"width": 217, "top": 1380, "height": 28, "left": 246}, "words": "(2)12个月(10000单位)"}, {"probability": {"variance": 3.5e-05, "average": 0.997814, "min": 0.97855}, "location": {"width": 204, "top": 1405, "height": 32, "left": 137}, "words": "【执行标准】《中国药典》"}, {"probability": {"variance": 0.008493, "average": 0.954731, "min": 0.503295}, "location": {"width": 692, "top": 1411, "height": 50, "left": 140}, "words": "【批准文号】国药准字H20057369(5000单位)、国药准字H20065348(10000单位)"}, {"probability": {"variance": 4e-06, "average": 0.998584, "min": 0.995225}, "location": {"width": 74, "top": 1458, "height": 24, "left": 155}, "words": "生产企业"}, {"probability": {"variance": 2.1e-05, "average": 0.997606, "min": 0.981368}, "location": {"width": 322, "top": 1469, "height": 37, "left": 181}, "words": "企业名称:北京双鹭药业股份有限公司"}, {"probability": {"variance": 1e-06, "average": 0.999393, "min": 0.9965}, "location": {"width": 473, "top": 1489, "height": 42, "left": 182}, "words": "生产地址:北京市石景山区八大处高科技园区中园路9号"}, {"probability": {"variance": 0.000246, "average": 0.988868, "min": 0.955712}, "location": {"width": 149, "top": 1526, "height": 26, "left": 183}, "words": "邮政编码:100041"}, {"probability": {"variance": 0.000494, "average": 0.989779, "min": 0.911297}, "location": {"width": 230, "top": 1546, "height": 29, "left": 185}, "words": "电话号码:010-88791675/77"}, {"probability": {"variance": 0.000124, "average": 0.995187, "min": 0.951356}, "location": {"width": 204, "top": 1570, "height": 29, "left": 185}, "words": "传真号码:010-88795883"}, {"probability": {"variance": 0.000166, "average": 0.986849, "min": 0.964631}, "location": {"width": 161, "top": 1597, "height": 26, "left": 184}, "words": "网址:http://"}, {"probability": {"variance": 0.014065, "average": 0.92705, "min": 0.690671}, "location": {"width": 41, "top": 1680, "height": 20, "left": 1146}, "words": "02-24"}], "language": -1}